# A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies

> **NCT00130169** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 30 (actual)

## Conditions studied

- Cancer, Malignant Tumors

## Interventions

- **DRUG:** E7974

## Key facts

- **NCT ID:** NCT00130169
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00130169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00130169, "A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00130169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*